Evidence map›Paper›PMID 29497863›Full record

ReviewCurrent diabetes reports2018

Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?

Ambreen Gul, Philip Zager

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Colorimetric and fluorometric determination of uric acid by a suspension-based assay using enzyme-immobilized micro-sized particles.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Article
  4. Hyperuricemia Predicts the Progression of Type 2 Diabetic Kidney Disease in Chinese Patients.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ambreen GulDialysis Clinic, Inc., Quality Management, 1500 Indian School Rd. NE, Albuquerque, NM, 87102, USA.
Philip ZagerDialysis Clinic, Inc., Quality Management, 1500 Indian School Rd. NE, Albuquerque, NM, 87102, USA. pzag@unm.edu.
University of New Mexico Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewMultiple experimental and clinical studies have identified pathways by which uric acid may facilitate the development and progression of chronic kidney disease (CKD) in people with diabetes. However, it remains uncertain if the association of uric acid with CKD represents a pathogenic effect or merely reflects renal impairment. RECENT

findingsIn contrast to many published reports, a recent Mendelian randomization study did not identify a causal link between uric acid and CKD in people with type 1 diabetes. Two recent multicenter randomized control trials, Preventing Early Renal Function Loss in Diabetes (PERL) and FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3 (FEATHER), were recently designed to assess if uric acid lowering slows progression of CKD. We review the evidence supporting a role for uric acid in the pathogenesis of CKD in people with diabetes and the putative benefits of uric acid lowering.

Indexed as

Diabetic NephropathiesDisease ProgressionHumansRenal Insufficiency, ChronicUric AcidUric AcidDiabetic nephropathyHyperuricemiaKidney diseaseType 1 diabetesType 2 diabetesUric acid

Identifiers

PMID29497863
OpenAlexW2792539994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.